Keyphrases
Anticoagulation
100%
Edoxaban
100%
Percutaneous Endoscopic Gastrostomy
100%
Amyotrophic Lateral Sclerosis
50%
Atrial Fibrillation
50%
Vitamin K Antagonists
33%
Direct Oral Anticoagulants
33%
Clinical Trials
16%
Clinical Practice
16%
Bleeding
16%
Steady State
16%
Type 2 Diabetes Mellitus (T2DM)
16%
Acute Respiratory Failure
16%
Older Men
16%
Patients with Heart Failure
16%
Tachycardia
16%
Hypertension
16%
Emergency Department
16%
Comorbidity
16%
Type 1 Diabetes Mellitus (T1DM)
16%
Dyspnea
16%
Peak Plasma Concentration
16%
Acute Heart Failure
16%
International Normalized Ratio
16%
Takotsubo Syndrome
16%
Non-valvular Atrial Fibrillation
16%
Intubated
16%
Rivaroxaban
16%
Control Time
16%
Time in Therapeutic Range
16%
Long-term Strategy
16%
Ratio Control
16%
Medicine and Dentistry
Anticoagulation
100%
Edoxaban
100%
Percutaneous Endoscopic Gastrostomy
100%
Atrial Fibrillation
66%
Amyotrophic Lateral Sclerosis
50%
Vitamin K Antagonist
33%
Direct Oral Anticoagulant
33%
Clinical Trial
16%
Bleeding
16%
Maturity Onset Diabetes of the Young
16%
Acute Respiratory Failure
16%
Tachyarrhythmia
16%
Emergency Department
16%
Steady State
16%
Congestive Heart Failure
16%
Dyspnea
16%
Thromboembolism
16%
Takotsubo Cardiomyopathy
16%
Rivaroxaban
16%
Acute Decompensated Heart Failure
16%
Comorbidity
16%
Pharmacology, Toxicology and Pharmaceutical Science
Edoxaban
100%
Atrial Fibrillation
66%
Normal Human
50%
Amyotrophic Lateral Sclerosis
50%
Antivitamin K
33%
Direct Oral Anticoagulant
33%
Clinical Trial
16%
Bleeding
16%
Acute Respiratory Failure
16%
Dyspnea
16%
Congestive Heart Failure
16%
Acute Heart Failure
16%
Thromboembolism
16%
Takotsubo Cardiomyopathy
16%
Tachycardia
16%
Rivaroxaban
16%
Non Insulin Dependent Diabetes Mellitus
16%
Comorbidity
16%